web analytics
12.3 C
Munich
Friday, May 14, 2021

Latest Updates on SANUWAVE Health, Inc. (OTCBB:SNWV)

SANUWAVE Health, Inc. (OTCBB:SNWV) continues to drop heavily on accelerating volume after the recent run up the stock made off its 52 week low of $0.042 to highs over $0.30. SNVW is a stock with a history of big moves running from pennies to well over $1.50 a share in early 2013.

On February 25 the Company announced the receipt of U.S. Pat. No. 8,961,441 from the U.S. Patent and Trademark Office entitled, “Medical Treatment System Including an Ancillary Medical Treatment Apparatus with an Associated Data Storage Medium.”

The patent includes twenty-two claims relating to medical treatment systems that use: an electronic medical treatment apparatus, an ancillary treatment apparatus, an ancillary data storage medium, a data reader, and a display.

SANUWAVE Health, Inc. (OTCBB:SNWV) is a shock wave technology company focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.

SNWV initial focus is regenerative medicine – utilizing noninvasive, acoustic shockwaves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures.

The Company’s lead regenerative product in the United States is the demaPACE ® device, which is in a supplemental Phase III clinical study for treating diabetic foot ulcers with possible FDA approval in 2016, subject to submission of satisfactory clinical study results. dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand.

SANUWAVE has a number of partnership opportunities as well for their shock wave technology for non-medical uses, including energy, water, food and industrial markets.

The shell was incorporated in Nevada as Rub Music Enterprises, Inc., in May 2004. The Company was focused on building a music library and establishing a catalogue of copyrighted songs that they intended to license to interested parties. The business failed and in November 2009 they changed their name to SANUWAVE Health, Inc.

In recent news SNWV said they have enrolled its 130th patient in the Phase III supplemental clinical trial using dermaPACE® for treating diabetic foot ulcers (DFU’s), which represents the number of patients the Company must enroll for the second interim analysis by the independent Data Monitoring Committee (DMC).

 To Find out the inside Scoop on SNWV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The DMC will perform an analysis on the entire 130 patient population once the patients have completed the twelve week efficacy analysis period. This is expected to be completed in the first quarter of 2015. After their review of the 130 patients, the DMC may recommend: 1) stopping enrollment because the dermaPACE has met the minimum success criteria as compared to sham-control, 2) increasing enrollment to 170 patients which is the next predefined patient analysis point, or 3) stopping the trial due to poor results.

Kevin Richardson, II, Chairman of the board of directors of SANUWAVE, stated, “We are very pleased to have reached this enrollment milestone in the supplemental clinical trial of dermaPACE to treat diabetic foot ulcers. We anticipate having the feedback from the Data Monitoring Committee regarding the 130 patients in the first quarter of 2015 and look forward to updating shareholders at that time.”

We have a Monster Pick Coming. Subscribe Right Now!

SNWV seems to have been significantly oversold when it reached a recent all-time low of $0.042. This is a Company with a strong cash position of $4,687,222 in the treasury that boasts small but growing revenues of $227,492 for the quarter ended September 30, 2014 up from $148,421 for the same period last year.

At current levels the stock is trading at a cash basis with little good will associated to the phase 3 clinical trials for the demaPACE ® device. SNWV is a Company that was trading well over $5 shortly after hitting the bb’s with many seed shareholders paying well over $2 a share. Currently trading at a $6.5 million market valuation SNWV is an explosive situation that is quickly attracting a fast growing following.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in SNWV either long or short and we have not been compensated for this article.

Ali Raza
A journalist, with experience in web journalism and marketing. Ali holds a master degree in finance and enjoys writing about cryptocurrencies and fintech. Ali’s work has been published on a number of cryptocurrency publications.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.